Les études LYSA présentées aux Congrès de l’ASCO et de l’EHA 2022
2 présentations orales et 4 posters animées par le LYSA au programme de ces éditions
Découvrez les différentes présentations de ces éditions 2022
ASCO - American Society of Clinical Oncology
1 poster
FLIRT:
Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study
Guillaume Cartron
EHA - European Hematology Association
2 présentations orales
DESCAR-T:
A matched comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory Diffuse Large B-cell Lymphoma: a real-life LYSA study from the French DESCAR-T registry
Emmanuel Bachy
CAR T-cells associated acute toxicity in B-cell Non-Hodgkin Lymphoma: real-world study from the DESCAR-T registry
Pierre Sesques
3 posters
REALYSA:
A large French real world multicentric prospective cohort of patients with lymphoma (REALYSA study): description of the Diffuse Large B-cell Lymphoma patients in real world in France
Hervé Ghesquières
Intrathecal Methotrexate prophylaxis and Central Nervous System relapse in patients with Diffuse Large B-cell Lymphoma treated with intensified R-ACVBP strategy
Loïc Renaud
FLIRT:
Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study
Guillaume Cartron
